USPTO Grants Patent for VISTA Inhibiting Antibody
1 report, 1 independent
Updated Oct 13
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The United States Patent and Trademark Office issued Patent No. 12,760,104, which covers a VISTA inhibiting antibody and related compounds. The patent claims extend to bispecific and multi-specific antibodies and methods of treatment that apply beyond cancer, including autoimmune disease and infection. The patent term is set to expire on February 18, 2042.
From prnewswire.com
Why it matters
The grant of this patent secures intellectual property rights for the therapeutic, providing market exclusivity for the antibody and its applications. This protection is critical for the company's revenue streams in the immuno-oncology and related treatment sectors.
From prnewswire.com
Who's involved
- United States Patent and Trademark OfficeAgency that formally granted the patent
Keep exploring
The entities involved
-
United States Patent and Trademark Office
agency in the United States Department of Commerce